Primary pleomorphic liposarcoma of the cecum case report.
| Autor: | Muiños AC; Oncologic Surgeon and Professor of General Surgery, Hospital Español, Mexico City, Mexico., Montes VG; Specialist in Medical Oncology, Hospital Español, Mexico City, Mexico., Carrasco JC; Oncologic Surgeon and Professor of General Surgery, Hospital Español, Mexico City, Mexico., Villanueva ÁFR; Coloproctologic Surgeon and Professor of General Surgery, Hospital Español, Mexico City, Mexico., García GDS; Resident of general surgery, Hospital Español, Mexico City, Mexico., Navarro EG; Resident of general surgery, Hospital Español, Mexico City, Mexico. Electronic address: gallardo18e@gmail.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of surgery case reports [Int J Surg Case Rep] 2024 Aug; Vol. 121, pp. 109961. Date of Electronic Publication: 2024 Jun 27. |
| DOI: | 10.1016/j.ijscr.2024.109961 |
| Abstrakt: | Introduction: The pleomorphic variant is the least common and consequently, the least known subtype of liposarcomas. It represents <5 % of all liposarcomas and develops during late adulthood. Presentation of the Case: We report the case of a 77-year-old male who presented with pain in the right iliac fossa and right inguinal region. A CT scan revealed a stony lesion at the level of the cecum. A right hemicolectomy was performed, and the pathology report was positive for pleomorphic liposarcoma. Consequently, he was referred for adjuvant radiotherapy. Clinical Discussion: Molecular analysis has validated the distinction of liposarcoma subtypes, although histological subtype remains the reliable prognostic parameter in daily practice, recent evidence suggests that genetic profiles may eventually influence risk stratification of individual patients. Conclusion: The pleomorphic subtype of liposarcomas is infrequent, and they are very rare in the cecum, so it is currently recommended that patients be evaluated by a multidisciplinary team to make a therapeutic decision as it is a subtype of very aggressive behavior, before initiating any type of oncologic treatment. Competing Interests: Declaration of competing interest The authors declare that they have no conflict of interest. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|